Emergent BioSolutions Announces Stock Repurchase Program
11 nov. 2021 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized management to repurchase up to $250 million of...
Emergent BioSolutions Reports Financial Results For Third Quarter 2021
04 nov. 2021 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2021. "Emergent's core...
Emergent BioSolutions to Release Third Quarter 2021 Financial Results and Conduct a Conference Call on November 4, 2021
18 oct. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, November 4, 2021 at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Announces Initiation of Pivotal Phase 3 Study Evaluating the Safety and Immunogenicity of Its Single-Dose Chikungunya Vaccine Candidate, CHIKV VLP
15 oct. 2021 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Oct. 15, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and...
Emergent BioSolutions Secures Multi-Year Development and Manufacturing Agreement with Providence Therapeutics for its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B
14 sept. 2021 08h00 HE
|
Emergent BioSolutions
Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021GAITHERSBURG, Md. and CALGARY, Alberta, Sept....
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
25 août 2021 06h30 HE
|
Emergent BioSolutions
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s COVID-19 Human Immune Globulin (COVID-HIG), for potential...
Emergent BioSolutions to Participate in Investor Conferences
23 août 2021 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s senior management team will participate in the following...
Emergent BioSolutions Reports Financial Results For Second Quarter 2021
29 juil. 2021 16h05 HE
|
Emergent BioSolutions
Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second...
Emergent BioSolutions to Resume Manufacturing Covid-19 Vaccine at Bayview Facility
29 juil. 2021 07h25 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 29, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview...
Reverse the Silence Campaign Casts a National Spotlight on Overdose Risks Associated with Opioid Use
26 juil. 2021 09h01 HE
|
Emergent BioSolutions
Emergent BioSolutions joins forces with an alliance of advocacy organizations that share a common goal to empower open communication and address the stigma of opioid overdoses, which are oftentimes...